A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay L, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA.
Schadendorf D, et al. Among authors: thakur m.
Future Oncol. 2025 Jan 14:1-12. doi: 10.1080/14796694.2024.2442851. Online ahead of print.
Future Oncol. 2025.
PMID: 39810544